Leading companies and market value
Overall world revenue for epigenetic applications will reach
in 2013, our report forecasts. The R&D pipeline is diverse and promising. That industry holds great potential for further investment, development and growth.
In our study you find discussions of these organisations and many others:• Celgene• Eisai• Merck & Co.• Roche• Astex Pharmaceuticals• Exact Sciences• Orion Genomics.
This decade, many opportunities will arise. Our work shows you the technological and commercial possibilities.
Nine ways Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 helps you
To sum up, our investigation gives you the following knowledge on the topic:
• Forecasted revenues to 2023 for the overall world market and 3 submarkets - you discover prospects for the industry's future
• Predicted revenues of 6 products to 2023 - you find prospects for drugs, both existing brands and those awaiting launch
• Market forecasting to 2023 for US,
, BRIC nations and
- you see national and regional outlooks
• Assessments of companies - you find activities, products, strategies and outlooks
• Review of R&D by technology and disease - you hear about progress in established and emerging research areas
• Opinions on the sector - you read our interviews with leaders in that industry
• Competition and opportunities influencing sales - you see what affects the future
• Discussions of what stimulates and restrains the industry and market - you explore business trends, drivers and restraints
• Prospects for established firms and those seeking to enter the sector - you assess needs, practices and outlooks for success.
You gain information found nowhere else
That work gives independent analysis from our primary and secondary research. You receive business intelligence found only in our study, seeing where prospects are lucrative.
With our report you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses and decisions, saving time and getting you recognition for technological and commercial insight.